Citations

Citations to this article as recorded by  

• Initiating foslevodopa infusion in Parkinson disease: a pragmatic study
  Antoniangela Cocco, Roberta Zangaglia, Giorgio Belluscio, Micol Avenali, Francesca Valentino, Rosaria Calabrese, Tiziana De Santis, Paola Polverino, Alberto Albanese
  Parkinsonism & Related Disorders.2026; 143: 108142.     CrossRef
• Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
  Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw
  Movement Disorders Clinical Practice.2025; 12(7): 1028.     CrossRef
• Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication
  Katarina Rukavina, Georg Ebersbach, Doreen Gruber
  Movement Disorders Clinical Practice.2025; 12(12): 2317.     CrossRef
• Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series
  Guillaume Baille, Nathalie Patte‐Karsenti, Quentin Salardaine, Hélène de Saint‐Vaulry, Jean‐Philippe Brandel, Clément Desjardins
  Movement Disorders Clinical Practice.2025;[Epub]     CrossRef
• Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
  Paolo Solla, Vittorio Velucci, Giovanni Defazio, Tommaso Ercoli
  Movement Disorders Clinical Practice.2025; 12(11): 2028.     CrossRef

Citations

Citations to this article as recorded by  

• Initiating foslevodopa infusion in Parkinson disease: a pragmatic study
  Antoniangela Cocco, Roberta Zangaglia, Giorgio Belluscio, Micol Avenali, Francesca Valentino, Rosaria Calabrese, Tiziana De Santis, Paola Polverino, Alberto Albanese
  Parkinsonism & Related Disorders.2026; 143: 108142.     CrossRef
• Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
  Tomonori Nukariya, Toshiki Tezuka, Shohei Okusa, Ryotaro Okochi, Yuto Sakai, Yoshihiro Nihei, Jin Nakahara, Morinobu Seki
  Journal of Movement Disorders.2025; 18(2): 179.     CrossRef
• Profile of People With Parkinson's Disease Treated With a Device‐Aided Therapy in Spain. A Comparative Multicenter Observational Study
  Diego Santos‐García, Ángela Solleiro, Guillermo González‐Ortega, Pablo Mir, Nuria López‐Ariztegui, Rocío García Ramos, Inés Legarda, Anna Planas‐Ballvé, Deborah Alonso‐Modino, Pilar Sánchez‐Alonso, Iria Cabo, Marta Blázquez‐Estrada, Álvaro Sánchez‐Ferro
  Movement Disorders Clinical Practice.2025;[Epub]     CrossRef
• Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication
  Katarina Rukavina, Georg Ebersbach, Doreen Gruber
  Movement Disorders Clinical Practice.2025; 12(12): 2317.     CrossRef
• Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series
  Guillaume Baille, Nathalie Patte‐Karsenti, Quentin Salardaine, Hélène de Saint‐Vaulry, Jean‐Philippe Brandel, Clément Desjardins
  Movement Disorders Clinical Practice.2025;[Epub]     CrossRef
• Atypical Psychosis in Parkinson Disease
  Lindun Ge, Yasuyoshi Kimura, Keita Kakuda, Kotaro Ogawa, Yuta Kajiyama, Kanako Asai, Seira Taniguchi, Goichi Beck, Yoshiyuki Nishio, Jee Hyun Kim, Kensuke Ikenaka, Hideki Mochizuki
  Neurology Clinical Practice.2025;[Epub]     CrossRef